domains within the liposome, a fraction of said polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane.

4. (Amended) The liposome delivery system of claim 1, comprising from about 5 % to about 40 % polymerizable colipid.

5. (Amended) The liposome delivery system of claim 1, wherein the liposome further comprises a steric stabilizer.

6. (Amended) The liposome delivery system of claim 5, comprising from about 2 % to about 20 % steric stabilizer.

7. (Amended) The liposome delivery system of claim 5, comprising from about 5 % to about 40 % polymerizable colipid and from about 2 % to about 20 % steric stabilizer.

8. (Amended) The liposome delivery system of claim 5, wherein the steric stabilizer is a poly (ethylene glycol).

9. (Amended) The liposome delivery system of claim 1, wherein said polymerizable colipid is selected from the group consisting of mono-, bis-, and heterobifunctional, diacetylenyl, acryloyl, methacryloyl, dienoyl, dienyl, sorbyl, muconyl, styryl, vinyl, and lipoyl colipid.

10. (Amended) The liposome delivery system of claim 1, further comprising a releasable agent.

11. (Amended) The liposome delivery system of claim 10, comprising from about 5 % to about 40 % polymerizable colipid.

12. (Amended) The liposome delivery system of claim 10, wherein the liposome further comprises a steric stabilizer.

13. (Amended) The liposome delivery system of claim 12, comprising from about 2 % to about 20 % steric stabilizer.

14. (Amended) The liposome delivery system of claim 12, comprising from about 5 % to about 40 % polymerizable colipid and from about 2 % to about 20 % steric stabilizer.

15. (Amended) The liposome delivery system of claim 12, wherein the steric stabilizer is a poly (ethylene glycol).

16. (Amended) The liposome delivery system of claim 10, wherein said polymerizable colipid is selected from the group consisting of mono-, bis-, and heterobifunctional, diacetylenyl, acryloyl, methacryloyl, dienoyl, dienyl, sorbyl, muconyl, styryl, vinyl, and lipoyl colipid.

17. (Amended) The liposome delivery system of claim 10, wherein the releasable agent is a water soluble molecule.

18. (Amended) The liposome delivery system of claim 10, wherein the releasable agent is a lipid associated molecule.

19. (Amended) A pharmaceutical composition comprising a liposome delivery system of claim 10, wherein the releasable agent is a therapeutic agent encapsulated in or associated with the liposome, and a pharmaceutically acceptable carrier or diluent.

23. (Amended) A pharmaceutical composition comprising a liposome delivery system of claim 10, wherein the releasable agent is a diagnostic agent encapsulated in or associated with the liposome, and a pharmaceutically acceptable carrier or diluent.

27. (Amended) A method of producing a liposome delivery system of claim 10, comprising the steps of:

(i) drying the lipids that comprise the liposome,

(ii) hydrating said lipids with a buffer, comprising agents to be encapsulated or associated in a desired molar ratio to create hydrated bilayers,

(iii) converting said bilayers into liposomes; and

(iv) purifying the liposomes.

30. (Amended) The method of Claim 27, wherein the bilayers are converted into liposomes by ultrasonification or freeze-thawing followed by extrusion.

33. (Amended) The radiation sensitive liposome of claim 32, wherein the peptide is selected from the group consisting of antibodies, antibody fragments, and antigens.

Please Add claims 34-36 to read as follows:

34. (New) The liposome delivery system of Claim 1, comprising PEG_{2000}-distearoylPE, cholesterol, distearolylPC and bis-$SorbPC_{17,17}$.

35. (New) The liposome delivery system of Claim 1, comprising PEG_{2000}-distearoylPE, distearolylPC and bis-$SorbPC_{17,17}$.

REMARKS

Entry of this amendment is respectfully requested. No new matter is added by the amendment, because the amended application is fully supported by the application as filed.

Claim 1 is now amended to require that the polymerizable colipid at least some of which are in the form of discrete domains within the liposome. This amendment is supported by the disclosure on page 17 and the original claim 2.